AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00607126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resistive training
Description: resistive training using theraband and/or weights
Study NCT01062009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate
Description: Zinc sulfate 200 mcg/ml in Normal Saline
Study NCT00856986 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: liraglutide
Description: Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
Study NCT00856986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
Study NCT02297815 — intervention group
Intervention type: DRUG
Intervention: Broad-spectrum antibiotics
Description: Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
Study NCT02297815 — intervention group
Intervention type: DRUG
Intervention: Narrow-spectrum antibiotics
Description: Amoxicillin, Penicillin
Study NCT01224327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord Mesenchymal Stem Cells
Description: Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
Study NCT01224327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved therapy
Description: Oral or intravenous administration
Study NCT02373046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
Study NCT02373046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
Study NCT03621072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole 150mg Capsule Originator
Description: 150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
Study NCT03621072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 150mg Capsule Localized Originator
Description: 150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
Study NCT04012827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate, doxorubicin, ifosfamide
Description: Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
Study NCT03665766 — intervention group
Intervention type: DRUG
Intervention: Cycloserine,Tacrolimus
Study NCT03026296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Life Center
Description: Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
Study NCT00252512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
Study NCT00252512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
Study NCT01007188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1.5PD almonds
Description: average American diet plus 1.5 oz per day almonds
Study NCT01007188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3.0PD almonds
Description: average American diet plus 3.0 oz per day almonds
Study NCT01007188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Base (without almonds)
Description: average American diet without almonds
Study NCT02014259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Study NCT02014259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Study NCT03965104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension Canada Professional Certification Program: HC-PCP
Description: The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
Study NCT03181971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water First
Description: The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
Study NCT01564251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0575
Description: Participants will receive GDC-0575 orally at a starting dose of 15 mg.
Study NCT01564251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
Study NCT01229683 — intervention group
Intervention type: PROCEDURE
Intervention: Interscalene Nerve Block
Description: Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
Study NCT03937388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cochlear stimulation strategy including time-fixed gaps
Description: Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
Study NCT04660695 — intervention group
Intervention type: DEVICE
Intervention: EUS-guided gastroenterostomy
Description: Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
Study NCT01048242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozerem
Description: Ramelteon (rozerem) 8mg oral before bedtime
Study NCT01048242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04454346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Foley Catheter For Ripening The Unfavorable Cervix
Description: New method
Study NCT00109213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion
Description: Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
Study NCT00109213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Laminectomy
Description: Removal of bone to decompress spinal nerves
Study NCT02364037 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHOICE Project Structured Contraceptive Counseling
Description: Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
Study NCT02364037 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contraceptive Education Session
Description: Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
Study NCT02364037 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cost Support for IUDs and implants
Description: Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
Study NCT01384565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF+EPO
Description: Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study NCT01384565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study NCT00816491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional white light colonoscopy
Description: conventional white light colonoscopy
Study NCT00816491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FICE (Fujinon Intelligent Chromoendoscopy)
Description: chromoendoscopy
Study NCT03293355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VPN
Description: Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
Study NCT04120246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-tocopheryloxyacetic Acid
Description: Given PO
Study NCT04120246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT03109743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sisters-GPS: Group Clinical Visits
Description: Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
Study NCT03109743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: One-on-one Adherence Counseling
Description: For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
Study NCT04111796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature based solution for stress reduction
Description: participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
Study NCT00856986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
Study NCT00856986 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: insulin detemir
Description: Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
Study NCT00856986 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metformin
Description: Metformin tablets, at least 1500 mg/day
Study NCT00856986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin tablets, at least 1500 mg/day
Study NCT01977196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT/HepatitisB/Hib vaccine
Description: DPT/HepatitisB/Hib vaccine (Bio Farma)
Study NCT03962907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun
Description: 5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
Study NCT03962907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BACTROBAN® Nasal ong
Description: Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
Study NCT00037440 — intervention group
Intervention type: GENETIC
Intervention: Polymorphisms measured
Study NCT03292874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: high resolution MRI (hrMRI)
Description: high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
Study NCT02761473 — intervention group
Intervention type: OTHER
Intervention: skin biopsy
Description: A skin biopsy will be obtained from a typical UP lesion in affected patients
Study NCT02761473 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: Blood will be obtained from subjects, parents and unaffected siblings
Study NCT03304041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low-FODMAPs diet
Description: The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks
Study NCT03304041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Traditional dietary advice
Description: Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks
Study NCT01727375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circadian light
Description: Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation.
Study NCT00358319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin
Study NCT00358319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Study NCT01135888 — intervention group
Intervention type: DEVICE
Intervention: Skin cooling devices
Description: Cooling vest and cooling bandana
Study NCT01999842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3206641A
Description: One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
Study NCT01999842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3206640A
Description: One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
Study NCT01999842 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
Study NCT03556085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous sinus stenting (Serenity River)
Description: Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
Study NCT05121467 — intervention group
Intervention type: OTHER
Intervention: Pain Assessment
Description: Visual Analogue Scale (VAS) were included in the study
Study NCT05121467 — intervention group
Intervention type: OTHER
Intervention: Assessment of Muscular Endurance
Description: The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
Study NCT05121467 — intervention group
Intervention type: OTHER
Intervention: Assessment of Neck Awareness
Description: The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
Study NCT05121467 — intervention group
Intervention type: OTHER
Intervention: Assessment of Fear of Movement
Description: The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
Study NCT05299346 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: Comprehensive follow up in dedicated follow up unit
Study NCT02355236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen/Esomeprazol 500/20mg
Description: Tablet, b.i.d.
Study NCT02355236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Capsule, o.d.
Study NCT02355236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naxozol-Placebo
Description: Tablet (which is identical to Naxozol), b.i.d.
Study NCT02355236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator-Placebo
Description: Capsule (which is identical to Celebrex), o.d.
Study NCT04164784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic monitoring
Description: According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
Study NCT01179984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard® LifeStent® Vascular Stent System
Description: Stent Implantation
Study NCT04177537 — intervention group
Intervention type: DEVICE
Intervention: Low Intensity Continuous Ultrasound
Description: 3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
Study NCT02462187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 8% Gel
Description: once and twice daily
Study NCT02462187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 16%
Description: once daily
Study NCT02462187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: placebo comparator
Study NCT02462187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 24%
Description: once daily